Back to ChemicalBook Home--->CAS DataBase List--->856866-72-3

856866-72-3

856866-72-3 Structure

856866-72-3 Structure
IdentificationBack Directory
[Name]

Torezolid
[CAS]

856866-72-3
[Synonyms]

DA 7157
DA-7157
Torezolid
Tedizolid
Torezolid (TR-701
Tedizolid (TR-701)
Tedizolid Impurity7
Tedizolid free base
Specially acetazolaMide
(R)-3-(3-Fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolid
3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-oxazolidi
-3-(4-(2-(2-Methyltetrazol-5-yl)pyridine-5-yl)-3-fluorophenyl)-5-hydroxyMethyl oxazolidin-2-one
3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-oxazolidinone
(R)-3-(4-(2-(2-Methyltetrazol-5-yl)pyridine-5-yl)-3-fluorophenyl)-5-hydroxyMethyl oxazolidin-2-one
3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
(5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-Oxazolidin
(R)-3-(3-fluoro-4-(6-(2-Methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxyMethyl)oxazolidin-2-one
(5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
3- [3-fluoro-4- [6- (2-methyl--2H- tetrazol-5-yl) -3-pyridinyl] phenyl] -5- (hydroxymethyl) -2-oxazolidine ketone
(5R)-3-{3-fluoro-4-[6-(2-Methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxyMethyl)-1,3-oxazolidin-2-one Phosphate
3-[3-Fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(hydroxymethyl)-2-oxazolidinone Torezolid (TR-701
[Molecular Formula]

C17H15FN6O3
[MDL Number]

MFCD19442562
[MOL File]

856866-72-3.mol
[Molecular Weight]

370.338
Chemical PropertiesBack Directory
[density ]

1.57
Hazard InformationBack Directory
[Uses]

Tedizolid, known as TR-700, is an oral and i.v administered intracellular antibacterial drug.
[Definition]

ChEBI: A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5 It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and meth cillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.
Safety DataBack Directory
[HS Code ]

29339900
Questions And AnswerBack Directory
[Novel antibacterial drugs]

Tedizolid belongs to the second generation oxazolidinone antibiotics, being an analog of linezolid as well as a kind of protein synthesis inhibitors, acting on the bacterial ribosomal 50S subunit and causing inhibition of bacterial protein synthesis. Compared with linezolid, the efficacy of the two is basically the same, but linezolid required to be taken for 2 times a day and for 10 continuous days while Tedizolid only takes 1 time daily and continuous taking for 6 days.
On June 20, 2014, the US FDA had approved a new antimicrobial drug Tedizolid (trade name: Sivextro) for the treatment of skin infections in adult patients. Sivextro is approved for the treatment of acute bacterial skin and skin infections caused by certain sensitive bacteria such as Staphylococcus aureus (including methicillin-resistant strains and methicillin-sensitive strains), various streptococci and Enterococcus faecalis (ABSSSI). Sivextro is administered intravenously and orally.
Tedizolid phosphate is a second-generation oxazolidinone antibiotic developed by Dong-A Pharmaceutical, licensed to Cubist Pharmaceuticals and Bayer for commercial development.
Sivextro is designed for the treatment of serious or life-threatening infections, and its listing applications are eligible for Qualified Infectious Disease Products (QIDP) and have obtained the approve of FDA for accelerated review. Sivextro's QIDP eligibility gives the drug exclusive five-year market exclusivity, in addition to its market exclusivity under the Food, Drug, and Cosmetic Act.
The safety and efficacy of Sivextro were evaluated in two clinical trials involving 1315 ABSSSI adult patients. Subjects were randomized to Sivextro or another antibiotic linezolid approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The results showed that its clinical efficacy is equivalent to linezolid. However, it will cause less gastrointestinal adverse reactions and thrombocytopenia adverse reactions than linezolid. The incidence of drug resistance is also lower. Tedizolid has been shown to be more tolerant than vancomycin.
The most common side effects identified in clinical trials include nausea, headache, diarrhea, vomiting and dizziness. The safety and efficacy of Sivextro have not been evaluated in patients with reduced white blood cell levels (neutropenia), so alternative therapies should be considered for these patients. Sivextro is marketed by Cubist Pharmaceuticals, Inc., based in Lexington, Massachusetts.
Status of intellectual property: Compound patent ZL200480037612.2, protection period 2024.12.17 expires.
This information was edited by Xiao Nan from Chemicalbook (2015-08-14).
[Indications]

Tedizolid phosphate is an oxazolidinone compound used in the treatment of acute bacterial skin and skin structure infections caused by the following gram-positive bacteria-sensitive strains: Staphylococcus aureus (including Methicillin-resistant and methicillin-susceptible strains), pyogenic streptococci, Streptococcus lactis, Streptococcus angustifolia (including Angina, Streptococcus intermedius and Streptococcus constellation), and Enterococcus faecalis.
[State of Intellectual Property]

(A) Administrative protection, new drug protection and new drug monitoring period
On August 9, 2013, Bayer Pharmaceuticals has filed a new drug application with CFDA.
(B) Domestic patent
1. Patented compounds
East Asia Pharmaceutical has applied for the compound patent in China under the application number is ZL200480037612.2. The date of application is December 17, 2004; the protection period will expire at 2024.12.17. Three subsequent divisional applications were further filed with the application numbers being 201010508824.1 (preparation), 201110304983.4, 201210155386.4.
On October 9, 2009, the Teresius Therapeutics Company has applied for a preparation method patent with the patent number of 200980140144.4.
2. Crystal patent
On February 3, 2010, Teulius Therapeutics applied for a crystalline form patent of free acid with the application number of 201080014363.0. Form I of the disclosed free acid has the advantage that it is more stable than the disodium salt and has no moisture absorption.
3. Formulation Composition Patents
The above-mentioned patent 200480037612.2 and its divisional application patent have disclosed the Tedizolid powder, tablet, capsule and injection.
The above-mentioned patent 201080014363.0 have disclosed the prescription of Tedizolid tablets and freeze-dried preparations.
856866-72-3 suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-66670886
Fax:
Website: https://www.dakenchem.com/
Company Name: Shanghai Bojing Chemical Co.,Ltd.
Tel: +86-21-37122233
Fax: +86-21-37127788
Website: www.bj-chem.com
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Fax: 0371-55170693
Website: www.tianfuchem.net
Company Name: Nanjing ChemLin Chemical Industry Co., Ltd.
Tel: 025-83697070;product@chemlin.com.cn
Fax:
Website: www.echemlin.cn
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +86 21 5161 9050/ 5187 7795
Fax: +86 21 5161 9052/ 5187 7796
Website: www.atkchemical.com
Company Name: career henan chemical co
Tel: +86-371-86658258
Fax:
Website: www.coreychem.com/index.html
Company Name: NINGBO INNO PHARMCHEM CO., LTD.
Tel: 13867897135
Fax:
Website: en.nbinno.com
Company Name: Zhejiang ZETian Fine Chemicals Co. LTD
Tel: 18957127338
Fax:
Website: www.zetchem.com
Company Name: Changzhou Ansciep Chemical Co., Ltd.
Tel: +86 519 86305871
Fax: +86 519 86305879
Website: www.chemicalbook.com/ShowSupplierProductsList31173/0.htm
Company Name: Hebei Guanlang Biotechnology Co., Ltd.
Tel: +8619930503282
Fax:
Website: https://www.chemicalbook.com/manufacturer/crovell/
Company Name: HubeiwidelychemicaltechnologyCo.,Ltd
Tel: 18627774460
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1110588/0.htm
Company Name: Standardpharm Co. Ltd.
Tel: 86-714-3992388
Fax:
Website: www.standardpharm.com
Company Name: BOC Sciences
Tel: 1-631-485-4226
Fax: 1-631-614-7828
Website: https://www.chemicalbook.com/ShowSupplierProductsList518419/0.htm
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-13650506873
Fax:
Website: http://www.chemdad.com/
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: 86-18523575427
Fax:
Website: https://www.canbipharm.com/
Company Name: Shaanxi Dideu Medichem Co. Ltd
Tel: 18192627656
Fax: +86-29-88380327
Website: www.chemicalbook.com/ShowSupplierProductsList54638/0.htm
Company Name: Zhuozhou Wenxi import and Export Co., Ltd
Tel: +8613111626072 (WhatsApp)
Fax: Wechat: +8613111626072 Wickr me: waynehu
Website: www.wenxichem-pharma.com
Company Name: Fuxin Pharmaceutical
Tel: 021-50872116
Fax:
Website: www.fuxinpharm.com
Tags:856866-72-3 Related Product Information
1256966-02-5 856867-41-9 65031-96-1 1220910-90-6 1700656-54-7 510729-01-8 55981-09-4 209860-87-7 366789-02-8 143491-57-0 120014-06-4 444335-16-4 1220910-89-3 380380-64-3 1056039-83-8 161973-10-0 198470-84-7 114870-03-0